DCM Ventures has raised $880 million across two funds that will continue its early-stage technology strategy, with 70% of the capital earmarked for deployment in China.
Japanese private equity firm J-Star has acquired regional restaurant chain Pepper Lunch for an undisclosed sum.
B Capital Group, a US-based VC with a presence in Singapore and a significant Asia portfolio, has closed its second global fund at $820 million.
Grindr, America's most popular LGBTQ dating app, was only put up for sale because its Chinese owner violated foreign investment regulations. San Vicente's subsequent $560 million acquisition faced intense scrutiny
Will Chinese companies listed in the US become the latest casualties of tensions between the two countries? It could lead to a narrowing in IPO exit options for PE and VC investors
China is the implied threat as governments look to protect vulnerable domestic companies from foreign corporate raiders. On balance, PE investors are unlikely to benefit from moves towards de-globalization
Big Idea Ventures, a US and Singapore-based food technology investor, has launched its debut fund with a target of $50 million. Asia is a core market.
US investors Optum Ventures and Health Catalyst Capital have co-led a $21.5 million Series A round for Singapore-based healthcare technology developer Holmusk.
Cathay Capital has closed its second middle-market fund, which invests in China, Europe and North America, with EUR800 million ($860 million) in commitments. The original target was EUR1.2 billion.
RWDC Industries believes it has a biodegradable substitute for plastic that can be produced at scale. The Singapore and US-based company now has $133 million in VC funding to help make its case
Lightspeed Venture Partners has raised $4 billion across early and growth-stage funds, including $1.5 billion for an opportunity fund that will support breakout companies in global markets such as China, India and Southeast Asia.
Zentalis Pharmaceuticals, a US-based cancer drug developer, raised $165.2 million in its NASDAQ IPO, facilitating a liquidity event for Chinese healthcare investment specialist HighLight Capital.
Capital Square Partners’ acquisition of Indian business processing outsourcing (BPO) player Aegis ultimately helped two different companies find global relevance after a turbulent and disruptive decade
Wanda Sports Group, the sports, media and marketing subsidiary of Chinese real estate conglomerate Wanda Group, has sold the Ironman brand to two US-based investors for an enterprise valuation of $730 million.
Accion Labs, a US-headquartered start-up with Asian operations that helps companies implement emerging technologies, has received a strategic growth investment by TA Associates.
Australian VC investor MH Carnegie has exited asset management software specialist Assetic to Dude Solutions, a similar private equity-owned company in the US.
Nature’s Fynd, a US-based developer of edible proteins from non-animal and non-plant sources that is seen as having considerable application potential in Asia, has raised $80 million in Series B funding.
Latin Leap, a Colombian VC investor and start-up services provider, has launched a boutique fund targeting $20 million to help Southeast Asian companies expand into Latin America.
Signs are converging that increased retail investor participation in private equity is inevitable. Myriad roadblocks around access, alignment, and infrastructure will inhibit the transition
Korea’s Mirae Asset Global Investments has led a $500 million Series F round for Impossible Foods, a US-based food technology supplier pursuing an Asia expansion.
Having assessed some 40 autonomous driving companies globally, Lightspeed China Partners decided that Hesai - a business born in the US and raised in China - is best-placed to take the technology forwards
Japan’s TDK Corporation has made a VC commitment of undisclosed size in AutoFlightX, an electric air mobility company based in Germany with a significant China presence.
China would suffer the most immediate impact of a technology decoupling with the US, but both sides would be damaged in the long-term in the absence of remedial action
The Everstone Group has agreed to invest $50 million in Slayback Pharma, a developer of generic and specialty drugs with a presence in India and the US.